OptiNose chooses BioClinica's advanced imaging and IWR solutions for clinical trials

BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that OptiNose, Inc. selected BioClinica Trident IWR, Optimizer clinical supplies forecasting, and Imaging Core Lab services for use in a series of clinical trials including several pivotal Phase III studies.

"OptiNose's goal was to employ the best available technology to help us develop the highest quality products in the most efficient manner," said Colette Kosik-Gonzalez, Senior Director, Clinical Development, OptiNose, Inc. "After a thorough competitive assessment of the leading solutions, we selected BioClinica for high-quality medical image management services and cutting-edge IVR technology to provide us with maximum efficiencies throughout our programs."

OptiNose's analysis found BioClinica Optimizer and Trident IWR products to be extremely user-friendly, with the added benefit of significantly reducing study build time. OptiNose also determined that the combination of Trident and Optimizer would ease trial management and help control costs by continually assessing clinical supply requirements throughout the trial.

"Award-winning technology and a talented services group are some of the reasons why innovative companies like OptiNose choose BioClinica's advanced imaging and IWR solutions," said Mark Weinstein, CEO of BioClinica. "BioClinica's approach to supporting clinical trials is based on the understanding that trial managers want better alternatives and fewer complications to support their clinical projects. With increasing frequency, clients realize the benefits of BioClinica's services suite and select multiple products to meet their needs. OptiNose is one such example of this trend, and we are pleased to help them manage their clinical trials with greater efficiency and accuracy."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Clario. (2019, June 24). OptiNose chooses BioClinica's advanced imaging and IWR solutions for clinical trials. News-Medical. Retrieved on November 02, 2024 from https://www.news-medical.net/news/20110908/OptiNose-chooses-BioClinicas-advanced-imaging-and-IWR-solutions-for-clinical-trials.aspx.

  • MLA

    Clario. "OptiNose chooses BioClinica's advanced imaging and IWR solutions for clinical trials". News-Medical. 02 November 2024. <https://www.news-medical.net/news/20110908/OptiNose-chooses-BioClinicas-advanced-imaging-and-IWR-solutions-for-clinical-trials.aspx>.

  • Chicago

    Clario. "OptiNose chooses BioClinica's advanced imaging and IWR solutions for clinical trials". News-Medical. https://www.news-medical.net/news/20110908/OptiNose-chooses-BioClinicas-advanced-imaging-and-IWR-solutions-for-clinical-trials.aspx. (accessed November 02, 2024).

  • Harvard

    Clario. 2019. OptiNose chooses BioClinica's advanced imaging and IWR solutions for clinical trials. News-Medical, viewed 02 November 2024, https://www.news-medical.net/news/20110908/OptiNose-chooses-BioClinicas-advanced-imaging-and-IWR-solutions-for-clinical-trials.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
BioClinica, CPI and Medtentia partner for eClinical and Imaging Core Lab solutions